
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
TRUMENBA (meningococcal group B vaccine)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
TRUMENBA Quick Finder
1 Health Professional Information
1 INDICATIONS
Trumenba (meningococcal group B vaccine [bivalent recombinant lipoprotein (rLP2086)]) is indicated for:
- active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
1.1 Pediatrics
Safety and efficacy of Trumenba in children below the age of 10 years of age have not been established (see 7.1.3 Pediatrics).
1.2 Geriatrics
Trumenba has not been studied in adults older than 65 years of age (see 7.1.4 Geriatrics).
2 Contraindications
Trumenba is contraindicated in individuals who are hypersensitive to the active ingredient or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
4 Dosage And Administration
4.2 Recommended Dose and Dosage Adjustment
Primary series
2 doses: (0.5 mL each) administered at a 6-month interval.
3 doses: 2 doses (0.5 mL each) administered at least 1 month apart, followed by a third dose at least 4 months after the second dose.
The choice of dosing schedule may depend on the risk of exposure and the subject’s susceptibility to meningococcal serogroup B disease.
Booster dose
A booster dose may be considered following either dosing regimen for individuals at continued risk of invasive meningococcal disease.
4.4 Administration
For intramuscular injection only. The preferred site for injection is the deltoid muscle of the upper arm.
The vaccine should be shaken vigorously to ensure that a homogeneous white suspension is obtained. Do not use the vaccine if it cannot be resuspended.
The vaccine should be visually inspected for particulate matter and discoloration prior to administration. This product should not be used if particulate matter or discolouration is found.
Separate injection sites and different syringes must be used if more than one vaccine is administered at the same time.
There are no data available on the interchangeability of Trumenba with other meningococcal serogroup B vaccines to complete the vaccination series.
4.5 Missed dose
If a dose of Trumenba is missed, individuals should contact their healthcare professionals for advice on appropriate series completion.
5 Overdosage
Experience of overdose is limited. Overdose with Trumenba is unlikely because it is provided in a prefilled syringe.
In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.
For management of a suspected drug overdose, contact your regional poison control centre.
6 Dosage Forms, Strengths, Composition and Packaging
To help ensure the traceability of vaccines for patient immunization record-keeping as well as safety monitoring, health professionals should record the time and date of administration, quantity of administered dose (if applicable), anatomical site and route of administration, brand name and generic name of the vaccine, the product lot number and expiry date.
Route of Administration |
Dosage Form / Strength/Composition |
Non-medicinal Ingredients |
---|---|---|
Intramuscular injection |
Suspension for injection 1 dose (0.5 mL) contains: Neisseria meningitidis serogroup B rLP2086 subfamily A 60 mcg Neisseria meningitidis serogroup B rLP2086 subfamily B 60 mcg |
Aluminum phosphate, histidine, polysorbate 80, sodium chloride and water for injection. |
Trumenba is a sterile liquid suspension for intramuscular injection supplied in a single-dose prefilled syringe.
Trumenba is supplied in cartons of 1 and 10 single-dose prefilled syringes, without needles. The tip cap and rubber plunger of the syringe are not made with natural rubber latex.
7 Warnings and Precautions
General
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
As with other injectable vaccines, syncope (fainting) can occur in association with administration of Trumenba. Procedures should be in place to avoid injury from fainting.
Do not inject intravenously, intradermally, or subcutaneously.
As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients.
Driving and Operating Machinery
Trumenba has no or negligible influence on the ability to drive or use machines. However, some of the effects (see 8 ADVERSE REACTIONS) may temporarily affect the ability to drive or use machines.
Hematologic
As with any intramuscular vaccine, Trumenba should be given with caution to individuals with thrombocytopenia or any coagulation disorder or to those receiving anticoagulant therapy, unless the potential benefit clearly outweighs the risk of administration.
Immune
There are no data available for immunocompromised individuals, including those receiving immunosuppressant therapy.
Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba.
Reproductive Health: Female and Male Potential
- Fertility
There are no data on fertility in humans.
Animal studies do not indicate direct or indirect harmful effects with respect to fertility in females (see 16 NON-CLINICAL TOXICOLOGY). Trumenba has not been evaluated for impairment of fertility in males.
7.1 Special Populations
7.1.1 Pregnant Women
There are no data from the use of Trumenba in pregnant women.
Reproduction studies performed in female rabbits at doses equivalent to the highest administered human dose have revealed no evidence of impaired female fertility or harm to the fetus due to Trumenba. Because animal reproductive studies are not always predictive of the human response, Trumenba should be used during pregnancy only if the potential benefits clearly outweigh the potential risks.
7.1.2 Breast-feeding
It is unknown whether Trumenba is excreted in human milk.
Trumenba should only be used during breast-feeding when the potential benefits outweigh the potential risks.
7.1.3 Pediatrics
Pediatrics (< 10 years of age): Safety and efficacy of Trumenba in children below the age of 10 years of age have not been established.
7.1.4 Geriatrics
Geriatrics (> 65 years of age): Trumenba has not been studied in adults older than 65 years of age.
8 Adverse Reactions
8.1 Adverse Reaction Overview
In clinical studies, the most common solicited adverse reactions were pain at the injection site, fatigue, headache, and muscle pain (see Tables 2 to 5). Nausea was reported in up to 22% of subjects in early phase studies. Most local and systemic reactions were mild or moderate in severity and resolved within 1 to 3 days after vaccination. The frequencies of solicited adverse reactions were highest after the first dose regardless of the schedule. The frequencies of solicited adverse reactions after subsequent doses were similar.
Overall, data for adverse events (AEs) summarized by age, sex, and race were comparable to AEs reported for the overall population.
8.2 Clinical Trial Adverse Reactions
Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials, therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.
The safety of Trumenba was investigated in 12 completed clinical studies conducted in the United States, Europe, Canada, Chile, and Australia (see 14 CLINICAL TRIALS) that enrolled a total of 21,860 subjects, of which 16,351 subjects received at least 1 dose of Trumenba (any dose level or vaccination regimen) administered alone or concomitantly with a licensed vaccine. A total of 5,509 control subjects received either saline alone, a licensed vaccine alone, or saline and a licensed vaccine. The core safety dataset comprises data derived from the 8 controlled studies for subjects 10-25 years of age who received at least 1 dose of Trumenba 120 mcg administered alone or concomitantly with a licensed vaccine on a schedule of 0, 2, and 6 months (n=13,284) or control vaccine (n=5,509) (Table 6).
The safety evaluation in the clinical studies included an assessment of: (1) solicited local and systemic reactions, and use of antipyretic medication after each vaccination in an electronic diary maintained by the subject or the subject’s parent/legal guardian; and (2) spontaneous reports of adverse events (AEs), including serious adverse events (SAEs) throughout the study (day of vaccination through 1 month or 6 months after the last vaccination, depending on the study and safety parameter).
Solicited Local and Systemic Reactions
Study B1971057 (Study 1057) was a Phase 3, randomized active-controlled, observer-blinded, multicenter trial in which 1057 subjects 10 through 25 years of age received at least 1 dose of Trumenba on a 0- and 6-month schedule. Trumenba was co-administered with meningococcal serogroups A,C,W,Y diphtheria CRM197 conjugate vaccine (MenACWY-CRM197) for the first dose.
Study B1971009 (Study 1009) was a Phase 3, randomized, active-controlled, observer-blinded, global, multicenter trial in which 2,693 subjects 10 through 18 years of age received at least 1 dose of Trumenba on a 0-, 2-, and 6- month schedule. A control group received hepatitis A virus vaccine (HAV) at 0 and 6 months and received saline at 2 months. Subjects were randomized to receive 1 of 3 lots of Trumenba or HAV/saline.
Study B1971016 (Study 1016) was a Phase 3, randomized, placebo-controlled, observer-blinded, global, multicenter trial in which 2,471 subjects 18 through 25 years of age received at least 1 dose of Trumenba or saline on a 0-, 2-, and 6- month schedule.
Tables 2, 3, 4 and 5 present the percentage of subjects who reported solicited local (Tables 2 and 3) and systemic (Tables 4 and 5) reactions, regardless of causality, within 7 days of each dose of Trumenba for Study 1057 and following each dose of Trumenba or control (hepatitis A virus vaccine [HAV]/saline or saline) for pivotal Phase 3 studies 1009 and 1016, which both included Canadian subjects.
|
Dose 1 |
Dose 2 |
---|---|---|
|
Trumenba+MenACWY-CRMa |
Trumenbaa |
Local Reaction |
N=1044 |
N=903 |
Painb |
||
Anyc |
85.0 |
82.2 |
Mild |
41.2 |
38.9 |
Moderate |
39.1 |
37.9 |
Severe |
4.7 |
5.4 |
Rednessd |
||
Anyc (>2.0 cm) |
16.9 |
14.7 |
Mild |
6.8 |
5.2 |
Moderate |
8.0 |
8.4 |
Severe |
2.0 |
1.1 |
Swellingd |
||
Anyc (>2.0 cm) |
17.0 |
14.3 |
Mild |
9.8 |
6.4 |
Moderate |
6.9 |
7.5 |
Severe |
0.3 |
0.3 |
a. Trumenba and MenACWY-CRM were administered at 0 month followed by Trumenba alone at 6 months. Local reactions were recorded at the Trumenba injection site only. b. Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity). c. "Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination. d. Mild (>2.0-5.0 cm); moderate (>5.0-10.0 cm); severe (>10.0 cm). |
Local Reaction |
Study 1009 |
Study 1016 |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trumenbaa |
HAV/Salinea |
Trumenbaa |
Salinea |
||||||||||
Dose 1 |
Dose 2 |
Dose 3 |
Dose 1 |
Dose 2 |
Dose 3 |
Dose 1 |
Dose 2 |
Dose 3 |
Dose 1 |
Dose 2 |
Dose 3 |
||
N=2681 |
N=2545 |
N=2421 |
N=890 |
N=843 |
N=821 |
N=2425 |
N=2076 |
N=1823 |
N=798 |
N=706 |
N=624 |
||
Painb |
|||||||||||||
Anyc |
86.7 |
77.7 |
76.0 |
47.0 |
15.2 |
34.0 |
84.2 |
79.3 |
80.4 |
11.8 |
7.8 |
6.7 |
|
Mild |
41.1 |
39.4 |
34.1 |
36.5 |
12.3 |
23.8 |
42.3 |
42.2 |
36.1 |
10.7 |
6.8 |
6.4 |
|
Moderate |
40.7 |
33.2 |
36.5 |
9.9 |
2.7 |
9.9 |
37.1 |
32.7 |
38.9 |
1.1 |
1.0 |
0.3 |
|
Severe |
5.0 |
5.1 |
5.4 |
0.6 |
0.1 |
0.4 |
4.8 |
4.4 |
5.3 |
0.0 |
0.0 |
0.0 |
|
Rednessd |
|||||||||||||
Anyc (≥ 2.5 cm) |
16.2 |
12.5 |
13.9 |
1.3 |
0.6 |
1.1 |
13.8 |
11.8 |
17.1 |
0.6 |
0.3 |
0.2 |
|
Mild |
5.6 |
5.2 |
4.9 |
1.2 |
0.6 |
1.0 |
5.8 |
4.6 |
6.2 |
0.5 |
0.1 |
0.2 |
|
Moderate |
8.8 |
6.1 |
6.8 |
0.1 |
0.0 |
0.1 |
7.1 |
6.3 |
8.6 |
0.0 |
0.0 |
0.0 |
|
Severe |
1.9 |
1.1 |
2.2 |
0.0 |
0.0 |
0.0 |
0.9 |
0.9 |
2.3 |
0.1 |
0.1 |
0.0 |
|
Swellingd |
|||||||||||||
Anyc (≥ 2.5 cm) |
18.0 |
13.9 |
15.4 |
2.2 |
0.6 |
0.9 |
15.5 |
14.0 |
16.6 |
0.6 |
0.4 |
0.3 |
|
Mild |
8.5 |
6.3 |
7.9 |
1.8 |
0.5 |
0.7 |
8.5 |
7.7 |
8.8 |
0.3 |
0.3 |
0.0 |
|
Moderate |
8.8 |
7.3 |
6.8 |
0.4 |
0.1 |
0.1 |
6.8 |
6.0 |
7.2 |
0.3 |
0.1 |
0.3 |
|
Severe |
0.7 |
0.2 |
0.7 |
0.0 |
0.0 |
0.0 |
0.2 |
0.3 |
0.5 |
0.1 |
0.0 |
0.0 |
|
a. Trumenba, hepatitis A virus vaccine (HAV)/saline, and saline were administered at 0, 2, and 6 months. b. Mild (does not interfere with activity); Moderate (interferes with activity); Severe (prevents daily activity) c. "Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination. d. Mild (2.5-5.0 cm); Moderate (5.5-10.0 cm); Severe (>10.0 cm). |
Systemic Reaction |
Dose 1 |
Dose 2 |
---|---|---|
Trumenba+MenACWY-CRMa |
Trumenbaa |
|
N=1044 |
N=903 |
|
Fever (≥38°C) |
||
≥38.0°C |
6.7 |
3.2 |
38.0°C to <38.5°C |
4.0 |
1.9 |
38.5°C to <39.0°C |
2.1 |
0.7 |
39.0°C to ≤40.0°C |
0.6 |
0.7 |
>40.0°C |
0.0 |
0.0 |
Vomitingb |
||
Anyc |
3.7 |
2.8 |
Mild |
2.9 |
2.0 |
Moderate |
0.9 |
0.8 |
Severe |
0.0 |
0.0 |
Diarrhead |
||
Anyc |
14.1 |
10.6 |
Mild |
10.7 |
7.6 |
Moderate |
3.3 |
2.5 |
Severe |
0.1 |
0.4 |
Headachee |
||
Anyc |
46.5 |
41.6 |
Mild |
25.1 |
23.1 |
Moderate |
19.0 |
16.5 |
Severe |
2.4 |
2.0 |
Fatiguee |
||
Anyc |
51.9 |
45.2 |
Mild |
25.4 |
23.0 |
Moderate |
23.7 |
19.2 |
Severe |
2.9 |
3.0 |
Chillse |
||
Anyc |
18.5 |
18.5 |
Mild |
11.5 |
11.6 |
Moderate |
5.7 |
6.2 |
Severe |
1.2 |
0.7 |
Muscle pain (other than muscle pain at the injection site)e |
||
Anyc |
28.4 |
21.4 |
Mild |
15.8 |
11.5 |
Moderate |
11.6 |
7.8 |
Severe |
1.1 |
2.1 |
Joint paine |
||
Anyc |
19.6 |
18.7 |
Mild |
10.2 |
11.2 |
Moderate |
8.6 |
6.5 |
Severe |
0.8 |
1.0 |
Use of antipyretic medication |
18.6 |
14.4 |
a. Trumenba and MenACWY-CRM were administered at 0 month followed by Trumenba alone at 6 months. b. Mild (1-2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration). c. “Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination. d. Mild (2-3 loose stools in 24 hours); moderate (4-5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours). e. Mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity). |
Systemic Reaction |
Study 1009 |
Study 1016 |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Trumenbaa |
HAV/Salinea |
Trumenbaa |
Salinea |
|||||||||
Dose 1 |
Dose 2 |
Dose 3 |
Dose 1 |
Dose 2 |
Dose 3 |
Dose 1 |
Dose 2 |
Dose 3 |
Dose 1 |
Dose 2 |
Dose 3 |
|
N=2681 |
N=2545 |
N=2421 |
N=890 |
N=843 |
N=821 |
N=2425 |
N=2076 |
N=1823 |
N=798 |
N=706 |
N=624 |
|
Fever (≥38°C)b,c |
||||||||||||
≥38.0°C |
6.4 |
2.0 |
2.7 |
1.9 |
1.5 |
2.3 |
2.4 |
1.2 |
2.0 |
0.6 |
1.0 |
0.6 |
38.0° to 38.5°C |
4.0 |
1.2 |
1.8 |
1.3 |
0.7 |
1.3 |
1.6 |
0.7 |
1.4 |
0.4 |
0.6 |
0.5 |
38.5° to 39.0°C |
1.9 |
0.7 |
0.6 |
0.3 |
0.7 |
0.4 |
0.7 |
0.4 |
0.4 |
0.0 |
0.3 |
0.2 |
39.0° to £40.0°C |
0.5 |
0.1 |
0.3 |
0.2 |
0.1 |
0.5 |
0.0 |
0.1 |
0.1 |
0.3 |
0.1 |
0.0 |
>40.0°C |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.1 |
0.0 |
0.0 |
0.1 |
0.0 |
0.0 |
0.0 |
Vomitingd |
||||||||||||
Anye |
3.7 |
2.2 |
1.7 |
1.9 |
1.4 |
2.2 |
2.6 |
2.1 |
2.0 |
2.1 |
1.6 |
1.4 |
Mild |
2.8 |
1.7 |
1.4 |
1.7 |
1.1 |
1.7 |
2.2 |
1.6 |
1.8 |
2.1 |
1.3 |
1.1 |
Moderate |
0.9 |
0.4 |
0.3 |
0.2 |
0.4 |
0.5 |
0.4 |
0.5 |
0.2 |
0.0 |
0.3 |
0.3 |
Severe |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Diarrheaf |
||||||||||||
Anye |
10.6 |
7.6 |
7.7 |
12.1 |
9.1 |
7.6 |
12.7 |
8.6 |
7.5 |
11.8 |
8.1 |
6.9 |
Mild |
9.1 |
6.2 |
6.4 |
10.9 |
7.6 |
6.2 |
10.2 |
6.4 |
6.1 |
9.8 |
4.7 |
5.3 |
Moderate |
0.3 |
1.3 |
1.0 |
1.1 |
1.2 |
1.1 |
2.4 |
1.7 |
1.2 |
1.9 |
2.8 |
1.3 |
Severe |
0.3 |
0.1 |
0.3 |
0.1 |
0.4 |
0.2 |
0.2 |
0.5 |
0.2 |
0.1 |
0.6 |
0.3 |
Headacheg |
||||||||||||
Anye |
51.8 |
37.8 |
35.4 |
37.2 |
28.1 |
24.8 |
43.9 |
33.1 |
32.5 |
36.2 |
24.9 |
21.6 |
Mild |
28.7 |
20.2 |
18.9 |
24.0 |
15.7 |
13.5 |
24.3 |
18.4 |
17.6 |
22.1 |
13.6 |
12.5 |
Moderate |
21.0 |
16.0 |
15.2 |
12.5 |
10.9 |
10.4 |
17.9 |
13.3 |
13.3 |
13.5 |
10.1 |
8.3 |
Severe |
2.2 |
1.7 |
1.3 |
0.7 |
1.5 |
1.0 |
1.6 |
1.4 |
1.6 |
0.6 |
1.3 |
0.8 |
Fatigueg |
||||||||||||
Anye |
54.0 |
38.3 |
35.9 |
40.3 |
26.3 |
24.4 |
50.9 |
39.2 |
39.3 |
39.8 |
27.3 |
24.5 |
Mild |
27.8 |
20.6 |
18.4 |
23.5 |
13.2 |
13.5 |
25.4 |
20.6 |
18.9 |
23.2 |
13.9 |
13.1 |
Moderate |
23.2 |
15.8 |
15.2 |
15.2 |
11.7 |
10.0 |
22.1 |
16.4 |
18.8 |
15.8 |
11.5 |
9.6 |
Severe |
3.0 |
1.9 |
2.3 |
1.7 |
1.4 |
0.9 |
3.4 |
2.2 |
1.6 |
0.9 |
2.0 |
1.8 |
Chillsg |
||||||||||||
Anye |
25.3 |
16.0 |
13.1 |
17.2 |
10.3 |
8.3 |
18.1 |
12.4 |
12.6 |
9.8 |
8.5 |
6.4 |
Mild |
16.2 |
10.6 |
8.7 |
13.3 |
8.1 |
6.5 |
12.0 |
8.1 |
7.7 |
8.1 |
6.9 |
4.3 |
Moderate |
8.0 |
4.8 |
3.8 |
3.5 |
1.8 |
1.7 |
4.9 |
3.5 |
4.2 |
1.6 |
1.6 |
2.1 |
Severe |
1.2 |
0.6 |
0.5 |
0.4 |
0.5 |
0.1 |
1.1 |
0.8 |
0.8 |
0.0 |
0.0 |
0.0 |
Muscle paing (other than muscle pain at injection site) |
||||||||||||
Anye |
24.4 |
17.8 |
17.6 |
19.2 |
10.3 |
11.1 |
25.9 |
15.6 |
16.9 |
14.5 |
8.5 |
7.5 |
Mild |
13.2 |
8.7 |
9.5 |
13.5 |
5.2 |
6.6 |
13.0 |
7.6 |
8.9 |
9.6 |
5.8 |
4.5 |
Moderate |
10.1 |
7.9 |
7.2 |
5.4 |
4.5 |
4.3 |
11.3 |
7.1 |
6.8 |
4.4 |
2.3 |
2.9 |
Severe |
1.2 |
1.2 |
0.8 |
0.3 |
0.6 |
0.2 |
1.6 |
0.8 |
1.2 |
0.5 |
0.4 |
0.2 |
Joint paing |
||||||||||||
Anye |
21.9 |
16.7 |
16.0 |
13.6 |
9.1 |
8.9 |
19.6 |
15.1 |
12.6 |
10.9 |
6.5 |
5.3 |
Mild |
11.8 |
8.4 |
8.9 |
8.3 |
5.0 |
5.5 |
10.3 |
8.1 |
6.6 |
6.9 |
3.7 |
2.9 |
Moderate |
8.7 |
7.5 |
5.9 |
4.6 |
3.4 |
3.0 |
7.9 |
6.2 |
5.4 |
3.5 |
2.5 |
2.4 |
Severe |
1.4 |
0.8 |
1.2 |
0.7 |
0.7 |
0.4 |
1.4 |
0.9 |
0.6 |
0.5 |
0.3 |
0.0 |
Use of antipyretic medication |
20.7 |
13.6 |
12.7 |
10.4 |
8.9 |
6.8 |
13.4 |
12.3 |
12.8 |
8.9 |
7.6 |
6.6 |
a. Trumenba, hepatitis A virus vaccine (HAV)/saline, and saline were administered at 0, 2, and 6 months. b. Study 1009: Fever (≥38°C): N=2679, 2540, and 2414 for Trumenba at Dose 1, Dose 2, and Dose 3, respectively; N=890, 840, and 819 for HAV/saline at Dose 1, Dose 2, and Dose 3, respectively. c. Study 1016: Fever (≥38°C): N=2415, 2067, and 1814 for Trumenba at Dose 1, Dose 2, and Dose 3, respectively; N=796, 705, and 621 for saline at Dose 1, Dose 2, and Dose 3, respectively. d. Mild (1-2 times in 24 hours); Moderate (>2 times in 24 hours); Severe (requires intravenous hydration). e. "Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination. f. Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools in 24 hours); Severe (6 or more loose stools in 24 hours). g. Mild (does not interfere with activity); Moderate (interferes with activity); Severe (prevents daily activity). |
Study 1042was a Phase 2 safety and immunogenicity study in US microbiology laboratory workers (n = 13, 24 to 62 years of age; 8 subjects >40 years of age) who received Trumenba on a 0, 2, 6-month schedule. No new safety signal was identified with the limited number of subjects.
Study B1971033 (Study 1033) was a Phase 3 open-label, follow-up study of subjects previously enrolled in a primary study, including Study B1971012 (Study 1012). Subjects attended visits over 4 years for collection of blood samples and received a single booster dose of Trumenba approximately 4 years after receipt of a primary series of 2 or 3 doses of Trumenba. Adverse reactions following booster vaccination in 301 subjects aged 15 through 23 years were similar to adverse reactions during the primary Trumenba vaccination series approximately 4 years earlier.
Adverse Events
In Study 1057 investigating the two-dose (0 and 6 months) schedule (N=1057), adverse events that occurred within 30 days of vaccination were reported in 255 (24.1%) subjects who received at least one dose of Trumenba.
In the 8 controlled studies (as described above) adverse events within 30 days after any dose were reported in 30.95% of subjects receiving Trumenba (n=13,284) and 28.37% of subjects in the control group (n=5,509). Adverse events that occurred at a frequency of at least 2% and were more frequently observed in subjects who received Trumenba than subjects in the control group were injection site pain (6.84% vs 3.59%), headache (3.78% vs 3.47%), and fever (2.61% vs 1.43%).
Serious Adverse Events
In Study 1057 and Study 1012 investigating the two-dose (0 and 6 months) schedule, serious adverse events (SAEs) were reported by 8 (0.8%) and 7 (1.6%) subjects who received at least one dose of Trumenba, respectively.
In the 8 controlled studies investigating the three-dose (0, 1-2, and 6 months) schedule, serious adverse events (SAEs) were reported by 1.6% and 1.9% of subjects who received at least one dose of Trumenba or control, respectively.
8.5 Post-Market Adverse Reactions
The following are considered adverse reactions for Trumenba and were reported in the post-marketing experience. Because these reactions were derived from spontaneous reports, the frequency could not be determined.
Immune system disorders: Allergic reactions
Nervous system disorders: Syncope (fainting)
9 Drug Interactions
9.4 Drug-Drug Interactions
Trumenba can be given concomitantly with any of the following vaccines: quadrivalent human papillomavirus vaccine (HPV4), meningococcal serogroups A, C, W, Y conjugate vaccine (MenACWY) and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) (see 14 CLINICAL TRIALS).
Do not mix Trumenba with other vaccines or products in the same syringe.
9.5 Drug-Food Interactions
Interactions with food have not been established.
9.6 Drug-Herb Interactions
Interactions with herbal products have not been established.
9.7 Drug-Laboratory Test Interactions
Interactions with laboratory tests have not been established.
10 Clinical Pharmacology
10.1 Mechanism of Action
Protection against invasive meningococcal disease is mediated by serum bactericidal antibodies to bacterial surface antigens. Bactericidal antibodies act in concert with human complement to kill meningococci. This process is measured in vitro with a serum bactericidal assay using human complement (hSBA). A positive response in the hSBA is the only accepted correlate of protection from meningococcal disease.
Factor H binding protein (fHbp) is a meningococcal surface-exposed antigen expressed by >95% of serogroup B strains. Factor H is a soluble glycoprotein found in human blood which regulates the alternative complement pathway and prevents the damage of human cells by complement. Meningococcal fHbp binds human factor H to prevent complement activation, allowing bacteria to avoid host immune defenses. Meningococcal fHbp variants segregate into two immunologically distinct subfamilies (designated A and B).
Trumenba is a bivalent vaccine composed of two recombinant lipidated factor H binding proteins – one each from subfamilies A and B. The lipidated protein (which is the naturally occurring form of fHbp) induces antibodies that can kill MnB strains expressing fHbps that are heterologous to those in the vaccine, whereas non-lipidated variants are unable to induce broadly cross-reactive bactericidal responses. Each Trumenba fHbp antigen elicits cross-protective responses against serogroup B strains expressing diverse fHbp variants from the same subfamily. Trumenba prevents serogroup B disease by inducing broadly protective bactericidal antibody responses against diverse fHbp variants expressed by serogroup B strains. Bactericidal antibodies elicited by Trumenba may also prevent factor H from binding to fHbp and render the bacteria more susceptible to complement-mediated killing.
Epidemiology
Invasive meningococcal disease is caused by the Gram-negative bacterium Neisseria meningitidis. Out of 12 known serogroups of N. meningitidis, serogroups B, C, W, and Y are most commonly reported in Canada. While healthy individuals (particularly adolescents and young adults) can carry N. meningitidis asymptomatically, invasive meningococcal disease (IMD) can progress rapidly. Invasive disease typically presents as meningitis and/or septicemia, and can have substantial consequences, with case fatality rates ranging from 5.3% to 10.7%. Approximately 19% of survivors suffer long-term sequelae.
Prior to 2001, serogroup C disease was most prevalent in Canada, representing approximately 40% of IMD cases. Following the introduction of routine serogroup C conjugate immunization programs starting between 2001 and 2005 in all provinces, a significant decline of serogroup C disease was noted, leaving serogroup B as the predominant disease-causing serogroup in Canada. In recent years (2013-2017), a total of 548 IMD cases were reported. The majority of cases were attributed to serogroup B (53%) which accounted for the largest proportion of cases in all age groups except in adults 60 years and older. During this period, an epidemic of serogroup B meningococcal disease has been observed in the province of Quebec1. In 2017, the incidence of IMD due to serogroup B was 0.13 cases per 100,000 population.2
When examining the age distribution of cases of serogroup B IMD reported by the Canadian Notifiable Disease Surveillance System (CNDSS), 37% of 669 cases reported between 2006 and 2011 occurred in children under 5 years of age; approximately 28% occurred in individuals 10-24 years of age and another 28% in individuals 25 years of age and older. The median age for contracting serogroup B IMD (2009-2011) was 16 years.3
The genotype of invasive serogroup B strains collected in Canada (2006-2012; n=258) as part of the Canadian Immunization Monitoring Program Active (IMPACT) surveillance network, including common epidemiological markers such as clonal complex (CC) and the fHbp variant type, has been determined. All isolates were found to contain the gene that codes for fHbp, with approximately 38% of strains expressing fHbp belonging to subfamily A and 62% to subfamily B. Consistent with findings from other countries, the distribution of Canadian strains expressing subfamily A and B differed as a function of patient age. Compared with adolescents and young adults, considerably more meningococcal disease in infants < 1 year of age and in patients ≥65 years of age was due to serogroup B isolates expressing subfamily A fHbp variants. Additionally, meningococcal carriage strains predominantly express subfamily A fHbp variants. A total of 50 different fHbp variants were identified in the IMPACT collection of MnB strains; however, 80% of the isolates expressed 1 of the following 10 most prevalent fHbp variants: B44, A22, B16, B09, A19, A05, A20, A12, B03, B24 (listed in order of decreasing prevalence). The CC profile of the Canadian MnB invasive isolates from 2006-2012 was largely composed of CC269 and CC41/44, representing approximately 39% and 29% of the total collection, respectively.4 Unlike IMD in other provinces, cases associated with the Quebec epidemic have been dominated by CC269 serogroup B strains, the majority of which express fHbp variant B44.
1. Zhou J, et al. J Clin Microbiol. 2012;50(15):1545-51.↩
2. https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/bivalent-factor-h-binding-protein-meningococcal-serogroup-b-prevention-meningococcal-b-disease.html ↩
3. Canada Communicable Disease Report (2014). Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. 2014 May 1; 40(9)↩
4. Reference for the genotype of predominant strains: Canadian Immunization Monitoring Program Active (IMPACT). Comparative Analysis of Canadian Neisseria meningitidis Serogroup B (MnB) Isolates. International Pathogenic Neisseria Conference 2014.↩
11 Storage, Stability and Disposal
Store in a refrigerator (2°C – 8°C).
Syringes should be stored in the refrigerator horizontally (laying flat on the shelf) to minimize the re-dispersion time. Do not freeze. Discard if the vaccine has been frozen.
Trumenba has been shown to be stable at temperatures of up to 25°C for 4 days. Cumulative multiple temperature excursions between 8°C and 25°C are permitted, as long as the total time does not exceed 4 days (96 hours). These data are not recommendations for shipping or storage, but may guide decisions for use in case of temporary temperature excursions.
12 Special Handling Instructions
Any unused product or waste material should be disposed of in accordance with local requirements.
Control #: 258009
October 11, 2022
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.